Drug intelligence / Profile preview

ophiopogonin D

Development stage: Unknown
Modality: Small Molecules
Administration: Oral, Intravenous, Intraperitoneal, Intragastric

Overview

Ophiopogonin D is a steroidal saponin compound isolated from the traditional Chinese herbal medicine *Ophiopogon japonicus* (Mai Dong). It is a potent antioxidant agent with multiple pharmacological activities including cardioprotective, anti-inflammatory, anti-cancer, anti-osteoporosis, and neuroprotective effects. The compound works through various mechanisms including modulation of the β-catenin/GPX4 signaling pathway, reduction of reactive oxygen species (ROS), and inhibition of ferroptosis. It has shown therapeutic potential for cardiovascular diseases, osteoporosis, cancer, and other conditions.

Other names: OP-DOphiopogonin D'

Targets

CTNNB1 (Beta-catenin)GPX4 (Glutathione peroxidase 4)

Beyond the preview

Go deeper on ophiopogonin D.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ophiopogonin D.

Explore the full profile